Radnet Stock Price, News & Analysis

RadNet (NASDAQ:RDNT), a leading outpatient diagnostic imaging services provider, reported record Q2 2025 results with total revenue increasing 8.4% to $498.2 million and Adjusted EBITDA growing 12.3% to $81.2 million. The company's Digital Health segment saw significant growth with revenue up 30.9% to $20.7 million.

Advanced imaging volumes showed strong performance, with MRI volume up 9.0%, CT volume up 8.1%, and PET/CT volume surging 22.4%. The company achieved Adjusted Earnings of $23.8 million ($0.31 per share), compared to $12.0 million ($0.16 per share) in Q2 2024.

Based on strong performance, RadNet revised its 2025 guidance upward, with total net revenue now projected at $1.85-1.90 billion and Adjusted EBITDA expected between $271-279 million.

DeepHealth, a RadNet (NASDAQ: RDNT) subsidiary, has received FDA 510(k) clearance for TechLive™, a remote scanning solution for MR, CT, PET/CT, and Ultrasound procedures. The vendor-agnostic platform enables centralized operation and supervision of multiple imaging systems simultaneously.

During a pilot deployment at 64 New York facilities, TechLive™ helped achieve a 42% reduction in MRI room closure hours in Q2 2025 compared to Q2 2024. The system has already been implemented across over 300 RadNet imaging systems, improving operational efficiency and increasing access to complex procedures.

RadNet (NASDAQ:RDNT), a leading provider of diagnostic imaging services and digital health solutions, has scheduled its second quarter 2025 financial results conference call for Monday, August 11, 2025 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

Investors can participate by dialing 844-826-3035 (US) or 412-317-5195 (International). A simultaneous webcast will be available, and an archived replay can be accessed using the passcode 10201853.

RadNet (NASDAQ:RDNT) has completed the acquisition of iCAD (NASDAQ:ICAD), a global leader in AI-powered breast health solutions, through its wholly-owned subsidiary DeepHealth. The strategic acquisition integrates iCAD's extensive AI portfolio for breast cancer detection with DeepHealth's screening solutions, expanding their reach to over 10 million mammograms annually.

iCAD's technology portfolio, deployed in more than 50 countries across 1,500+ healthcare provider locations, includes solutions for breast cancer detection, risk evaluation, breast density, and arterial calcification assessment. The combination aims to enhance AI model performance and accelerate the adoption of advanced breast cancer screening technologies worldwide, particularly in underserved communities.

RadNet (NASDAQ:RDNT), a leading outpatient diagnostic imaging services provider, announced that Regal Medical Group, Lakeside Community Healthcare, and ADOC Medical Group will include RadNet's Enhanced Breast Cancer Detection (EBCD) program in their members' health plans.

These medical groups, serving nearly 600,000 members across Southern California, will provide AI-powered breast cancer detection services to all mammogram-eligible patients. RadNet will implement a patient outreach program to boost compliance with annual screening guidelines. The program represents significant progress in securing EBCD reimbursement from commercial payors.

The collaboration aims to improve early breast cancer detection, as one in eight women will develop breast cancer in their lifetime. The AI-powered EBCD program can detect breast cancer earlier than traditional methods, potentially improving patient outcomes through earlier intervention.

RadNet (NASDAQ: RDNT) has acquired See-Mode Technologies, an AI innovator in ultrasound imaging diagnostics. See-Mode's FDA-approved AI solutions for thyroid and breast ultrasound detection will be integrated into RadNet's DeepHealth population health solutions. The acquisition demonstrates significant operational benefits, with early deployment showing up to 30% reduction in scan time across RadNet's imaging centers. RadNet performs approximately 250,000 annual thyroid ultrasounds and over two million total ultrasound studies yearly across 900+ units. The integration aims to improve diagnostic accuracy, enhance workflow efficiency, and generate standardized reports. The acquisition strengthens RadNet's position in AI-powered healthcare solutions, particularly in addressing thyroid and breast cancer diagnostics, which represent approximately 20 million ultrasound exams annually in the US alone.

RadNet (RDNT) reported Q1 2025 financial results with total revenue increasing 9.2% to $471.4 million despite weather-related challenges. The company's Digital Health segment saw strong growth with revenue up 31.1% to $19.2 million. However, Adjusted EBITDA decreased 20.6% to $46.4 million, primarily due to a $15 million impact from Southern California wildfires and severe winter weather. The company reported an Adjusted Loss Per Share of $(0.35) compared to earnings of $0.07 in Q1 2024. Notably, RadNet announced plans to acquire iCAD to enhance AI-powered breast cancer detection capabilities. Based on strong business recovery and positive trends, RadNet revised its 2025 guidance upward, with revenue now expected between $1.835-$1.885 billion and Adjusted EBITDA between $268-$276 million.

RadNet (NASDAQ: RDNT), a leading national provider of diagnostic imaging services, announced that Executive Vice President and CFO Mark Stolper will present at the Bank of America Securities 2025 Healthcare Conference. The presentation is scheduled for May 13, 2025, at 5:00 p.m. Pacific Time at the Encore Hotel in Las Vegas, NV.

RadNet operates 398 outpatient imaging centers across eight states including Arizona, California, Delaware, Florida, Maryland, New Jersey, New York, and Texas. The company provides diagnostic imaging services, radiology information technology, AI solutions through DeepHealth, and teleradiology services. RadNet employs over 11,000 people, including contracted radiologists, full-time and per diem employees, and technologists.

GE HealthCare (GEHC) will showcase its latest breast health technology advancements at the 2025 Society of Breast Imaging Symposium in Colorado Springs. The company is featuring several key innovations:

The Pristina Via™ mammography system offers streamlined workflows with zero-click acquisition, no wait time between exposures, and faster DBT image-to-image cycle times. The company will distribute DeepHealth's SmartMammo™, an AI-powered solution for breast cancer screening, now commercially available in the U.S.

Additional innovations include the Invenia™ ABUS Premium, the first FDA-approved breast ultrasound for dense breast detection, showing a 35.7% increase in cancer detection when used with mammography. The company also presents SenoBright™ HD and SerenaBright™, the first FDA-cleared Contrast Enhanced Mammography and CEM biopsy solutions.